Sensei Biotherapeutics, Inc.

Analysis for Ticker: SNSE

Sensei Biotherapeutics Inc is a clinical-stage business that claims to be developing new immunotherapies for cancer. The company is a shell designed to facilitate a 1.800% inflation of its own stock. The company has 1,3 million regular shares in existence, but is legally moving to dump 24,8 million new shares onto the market. A syndicate of hedge funds, including Baker Brothers and RA Capital, paid an effective price of only 13,85$ per share for this new equity, which is less than half of the 31,79$ price retail investors were paying in late 04/2026. If the existing owners do not vote to allow this massive dilution at the 10/06/2026 annual meeting, the funds have the power to demand all 200$ million of the company cash back by 17/08/2026. This is not an investment in science; it is a meticulously engineered drip feed where private funds extract value from the public before the company burns through its final reserves. To understand how the math became this broken, we have to look back at how the mechanism started in 02/2021. An insider named James Peyer and his company, Cambrian BioPharma, spent over one year buying up tiny pieces of stock in dozens of small open-market purchases. By 06/2025, the business was in such poor health that they executed a one-for-twenty reverse stock split to artificially inflate the share price on the computer screens. A reverse split does not make a company more valuable; it just takes twenty old shares and turns them into one new share so the price looks higher. By 10/2025, the company officially abandoned its main medicine, solnerstotug, and stopped all preclinical research while carrying an accumulated deficit of 278,4$ million.